Bryant Furlow

Fewer patients diagnosed with testicular cancer were uninsured, and fewer were diagnosed with late-stage disease, following the Affordable Care Act’s Medicaid enrollment expansion.

Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.

Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial. 

Researchers are developing a prognostic hypoxia gene signature for patients with localized prostate cancer that could predict biochemical failure and metastasis.

A newly developed clinical model can predict overall survival for patients diagnosed with advanced bladder cancer who are treated with atezolizumab.

Adding docetaxel chemotherapy to frontline hormone therapy improves quality of life and may reduce the need for subsequent treatment, according to an analysis from the STAMPEDE trial.

Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.

Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.

Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.

Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.

Immunochemotherapy should remain the standard induction approach for patients with high-risk follicular lymphoma.

Do you know which molecular markers signify poor-risk disease in AML? And how about what makes AML a challenging disease to manage in older adult patients? Test your knowledge in our latest quiz.

Which somatic mutation do most high-grade serous ovarian carcinomas harbor? And what percentage of endometrioid endometrial tumors have copy-number alterations? Test your knowledge in our latest quiz.

Is the use of bisphosphonates in patients with multiple myeloma associated with improved progression-free or overall survival? Is hypertension a risk factor for carfilzomib-related cardiopulmonary toxicities? Test your knowledge in our latest quiz.

Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.

Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.

Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the phase III RELEVANCE trial.

Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone improves overall survival compared with lenalidomide and dexamethasone alone.

Which genetic mutation confers shorter progression-free survival in myelofibrosis patients undergoing allogeneic stem cell transplantation? And what is the only potentially curative treatment for primary myelofibrosis? Test your knowledge in our latest quiz.

Survival disparities for black patients with ovarian, colon, and breast cancer and childhood ALL suggest a need for efforts toward improved screening and treatment adherence in this population.

The FDA approved bosutinib (Bosulif) for use as a treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia.

Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.

A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.

Adding rituximab to MBVP induction chemotherapy does not improve outcomes for patients with primary central nervous system lymphoma.

Patient access to NCI Cancer Centers is influenced by a complex mix of cancer center distribution and density, ethnicity, urbanicity, and travel time to care, according to a recently published statistical model.

Researchers have discovered that testicular cancer’s responsiveness to conventional chemotherapy is likely determined during prenatal development.

Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced nausea and vomiting compared with 5-HT3 and dexamethasone alone.

An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.

Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.

Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.